News Neurizon Therapeutics Limited

Equities

NUZ

AU0000357261

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 11:25:40 08/07/2025 am IST			5-day change	1st Jan Change
0.1550 ^AUD	0.00%		0.00%	-8.82%

03/07	Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel	MT
02/07	Neurizon Therapeutics Secures License Deal With Animal Health Company; Shares Up 3%	MT

Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel	03/07	MT
Neurizon Therapeutics Secures License Deal With Animal Health Company; Shares Up 3%	02/07	MT
Neurizon Therapeutics Develops Oral Liquid Formulation for Amyotrophic Lateral Sclerosis Drug Candidate	26/06	MT
Neurizon Therapeutics Says High Levels of NUZ-001 Drug Candidate Cross Blood-Brain Barrier in Rodent Study	20/06	MT
NUZ-001 Shows Promise In Zebrafish Model Of Huntington's Disease	16/06	RE
Neurizon® Therapeutics Limited Announces New Preclinical Data Demonstrating Significant Neuroprotective Effects of Nuz-001 Sulfone	16/06	CI
Neurizon Therapeutics Limited Announces Change of Registered Office and Principal Place of Business Address	02/06	CI
Neurizon Reports No Adverse Events as Final Patient Completes Sclerosis Drug Trial; Shares Fall 4%	05/05	MT
Neurizon Therapeutics Appoints Don O'Connell as Chief Financial Officer; Shares Down 4%	22/04	MT
Neurizon Therapeutics Appoints Dan O'Connell As CFO	22/04	RE
Neurizon Therapeutics Limited Appoints Dan O'Connell as Chief Financial Officer	22/04	CI
Neurizon Therapeutics Makes Three Executive Appointments; Shares Up 15%	17/04	MT
Neurizon Therapeutics Completes Study of Drug Candidate on Mouse Motor Neuron Cell Line	04/04	MT
Neurizon Therapeutics Limited Announces Results from an Additional Independent Study Carried Out in Partnership with the University of Queensland	04/04	CI
Neurizon Therapeutics Limited Announces Results from an Independent Study Conducted in Collaboration with Tessara Therapeutics	01/04	CI
ASX Biggest Gainers	28/03	MT
Neurizon Therapeutics Limited(ASX:NUZ) dropped from S&P/ASX Emerging Companies Index	24/03	CI
Neurizon Therapeutics Limited Provides Update on Preparation for Entry into the Healey & AMG Center	24/03	CI
Neurizon Therapeutics Moves to Lift FDA Suspension on NUZ-001 Drug Candidate with Two Studies; Shares Fall 5%	17/03	MT
Neurizon Therapeutics Logs HY Loss Attributable A$7.3 Mln	17/02	RE
Neurizon Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2024	17/02	CI
Neurizon Therapeutics Says Got Guidance From FDA Placing IND Application For NUZ-001 Under Clinical Hold	17/02	RE
Neurizon Gets US Patent for Cancer Drug Candidate; Shares Up 16%	05/02	MT
Neurizon Therapeutics Says US Patent Granted For NUZ-001	05/02	RE
Neurizon Therapeutics Says FDA Places its Investigational New Drug Application on Hold; Shares Hit New 52-Week Low	17/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Neurizon Therapeutics Limited

Equities

NUZ

AU0000357261

Pharmaceuticals

Filters